RTP Mobile Logo
Year in Review: Proceedings from a Multitumor CME Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers 2015
Released April 2016

Proceedings from a daylong symposium featuring key clinical presentations and papers in breast cancer, genitourinary cancers, Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia, multiple myeloma, gastrointestinal cancers, dermatologic cancers and non-small cell lung cancer. Also features an interactive component in which users can see how their responses to a number of pertinent clinical questions compare to those of the audience from all 4 cities visited during this regional series.

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

    OVERVIEW OF ACTIVITY
    Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    These proceedings from a daylong symposium combine the perspectives of 17 renowned investigators with a review of key recent presentations and publications across breast cancer, genitourinary cancers, Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia, multiple myeloma, gastrointestinal cancers, dermatologic cancers and non-small cell lung cancer to assist clinicians in the formulation of up-to-date management strategies.

    LEARNING OBJECTIVES

    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers.
    • Compare and contrast the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers, and refer appropriate patients for study participation.
    • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
    • Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeu­tics in order to offer supportive management strategies.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of video and interactive text components.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Johanna C Bendell, MD
    Director, GI Oncology Research
    Associate Director, Drug Development Unit
    Sarah Cannon Research Institute
    Nashville, Tennessee

    No relevant conflicts of interest to disclose.

    Kimberly L Blackwell, MD
    Professor of Medicine
    Director, Breast Cancer Program
    Duke Cancer Institute
    Durham, North Carolina

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sandoz; Contracted Research: Celgene Corpora­tion, Genentech BioOncology, Pfizer Inc.

    Howard A Burris III, MD
    Chief Medical Officer
    Executive Director, Drug Development
    Sarah Cannon Research Institute
    Nashville, Tennessee

    No relevant conflicts of interest to disclose.

    Adil Daud, MD
    Professor of Medicine
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: Amgen Inc, Genentech BioOncology, GlaxoSmithKline, OncoSec Medical; Consulting Agreements: Bristol-Myers Squibb Company, Merck, Novartis Pharmaceuticals Corporation, OncoSec Medical, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corpo­ration, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.

    Charles G Drake, MD, PhD
    Co-Director, Multi-D Prostate Cancer Clinic
    Professor of Oncology, Urology and Immunology
    Johns Hopkins Sidney Kimmel Cancer Center
    Baltimore, Maryland

    Consulting Agreements: Amplimmune Inc, Bristol-Myers Squibb Company, Compugen, Dendreon Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, ImmuneXcite Inc, ImmuNext Inc, Novartis Pharmaceuticals Corporation, Potenza Therapeutics, Roche Laboratories Inc, Sanofi; Patents: Amplimmune Inc, Bristol-Myers Squibb Company, Potenza Therapeutics; Stock Ownership: Compugen, ImmuneXcite Inc, ImmuNext Inc.

    Michelle A Fanale, MD
    Associate Professor
    Department of Lymphoma and Myeloma at
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Merck, Spectrum Pharmaceuticals Inc; Contracted Research: Bristol-Myers Squibb Company, Celgene Corpora­tion, Genentech BioOncology, Gilead Sciences Inc, MedImmune Inc, Merck, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Seattle Genetics, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc; Honoraria: Merck, Seattle Genetics, Spectrum Pharma­ceuticals Inc, Takeda Oncology.

    Axel Grothey, MD
    Professor of Oncology
    Department of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceu­ticals Inc, Boston Biomedical Pharma Inc, Celgene Corporation, Genentech BioOncology, Lilly; Contracted Research: Bayer HealthCare Pharmaceu­ticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Eisai Inc, Genentech BioOncology, Lilly, Merck, Sanofi.

    Roy S Herbst, MD, PhD
    Ensign Professor of Medicine (Oncology)
    Professor of Pharmacology
    Chief of Medical Oncology
    Director, Thoracic Oncology Research Program
    Associate Director for Translational Research
    Yale Comprehensive Cancer Center
    Yale School of Medicine
    New Haven, Connecticut

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Biothera, Bristol-Myers Squibb Company, Diatech, Genentech BioOncology, Kolltan Pharmaceuticals Inc, Lilly, NotI Microarrays; Consulting Agree­ments: Merck, Pfizer Inc.

    Brad S Kahl, MD
    Professor of Medicine
    Washington University School of Medicine
    St Louis, Missouri

    Consulting Agreements: Celgene Corporation, Genentech BioOncology, Takeda Oncology.

    Corey J Langer, MD
    Director of Thoracic Oncology
    Abramson Cancer Center
    Professor of Medicine
    Perelman School of Medicine
    University of Pennsylvania
    Vice Chair, Radiation Therapy Oncology Group
    Philadelphia, Pennsylvania

    Advisory Committee: Abbott Laboratories, Boehringer Ingelheim Pharma­ceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Novartis Pharmaceuticals Corpora­tion, Pfizer Inc; Consulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Pfizer Inc; Contracted Research: Astellas Pharma Global Development Inc, Celgene Corpora­tion, Genentech BioOncology, GlaxoSmithKline, Merck; Data and Safety Monitoring Board: AbbVie Inc, Amgen Inc, Lilly, Peregrine Pharmaceuti­cals Inc, Synta Pharmaceuticals Corp.

    Evan J Lipson, MD
    Assistant Professor, Medical Oncology
    Melanoma and Cancer Immunology Programs
    Johns Hopkins University School of Medicine
    The Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland

    Advisory Committee: Amgen Inc, Castle Biosciences Incorporated; Consulting Agreements: Bristol-Myers Squibb Company, Merck.

    Sagar Lonial, MD
    Professor
    Vice Chair of Clinical Affairs
    Director of Translational Research
    B-Cell Malignancy Program
    Department of Hematology and Medical Oncology
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

    Advisory Committee and Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceu­ticals, an Amgen subsidiary, Sanofi, Takeda Oncology.

    Craig Moskowitz, MD
    Clinical Director
    Division of Hematologic Oncology
    Attending Physician
    Lymphoma and Adult BMT Services
    Member
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Medical College of Cornell University
    New York, New York

    Consulting Agreements: Celgene Corporation, Genentech BioOncology, Merck, Seattle Genetics; Contracted Research: Merck, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics.

    William K Oh, MD
    Chief, Division of Hematology and Medical Oncology
    Professor of Medicine and Urology
    Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
    Mount Sinai School of Medicine
    Associate Director of Clinical Research
    The Tisch Cancer Institute
    Mt Sinai Health System
    New York, New York

    Advisory Committee: Bayer HealthCare Pharma­ceuticals, Bellicum Pharmaceuticals Inc, DAVA Oncology, Inovio Pharma­ceuticals, Janssen Biotech Inc, Sanofi, Seattle Genetics, Teva Oncology.

    Ruth O’Regan, MD
    Division Head of Hematology and Oncology
    Department of Medicine
    University of Wisconsin
    Madison, Wisconsin

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc.

    S Vincent Rajkumar, MD
    Professor of Medicine
    Division of Hematology
    Chair, Myeloma Amyloidosis Dysproteinemia Group
    Mayo Clinic
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    Michael E Williams, MD, ScM
    Byrd S Leavell Professor of Medicine
    Chief, Hematology/Oncology Division
    University of Virginia School of Medicine
    Charlottesville, Virginia Advisory Committee: Celgene Corporation, Takeda Oncology, TG Therapeutics Inc; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Takeda Oncology, TG Therapeu­tics Inc; Contracted Research: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Amgen Inc, Astellas Pharma Global Development Inc/Medivation Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, bioTheranostics Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eisai Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Merck, Merrimack Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Seattle Genetics, Taiho Oncology Inc and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2016
    Expiration date: April 2017

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
    application/pdf icon ADDITIONAL RESOURCES:
    Module 1: Breast Cancer
    Part 1:
    Dr Blackwell
    Part 2:
    Dr Burris
    Part 3:
    Dr O’Regan
    Module 2: Genitourinary Cancers
    Part 1:
    Dr Drake
    Part 2:
    Dr Oh
    Module 3: Hodgkin and
    Non-Hodgkin Lymphomas
    Part 1:
    Dr Williams
    Part 2:
    Dr Kahl
    Part 3:
    Dr Fanale
    Part 4:
    Dr Moskowitz
    Module 4: Multiple Myeloma
    Part 1:
    Dr Rajkumar
    Part 2:
    Dr Lonial
    Module 5: Colorectal, Gastric
    & Pancreatic Cancer
    Part 1:
    Dr Grothey
    Part 2:
    Dr Bendell
    Module 6: Dermatologic Cancers
    Part 1:
    Dr Daud
    Part 2:
    Dr Lipson
    Module 7: Non-Small Cell Lung Cancer
    Part 1:
    Dr Langer
    Part 2:
    Dr Herbst